Full-Time

People & Culture Business Partner

Posted on 5/16/2026

Roche

Roche

1-10 employees

Global pharmaceuticals and diagnostics company

No salary listed

Mumbai, Maharashtra, India

In Person

Requires 25-30% travel across India.

Category
People & HR (1)
Required Skills
Data Analysis
Requirements
  • Ten+ years of broad, progressive HR management or consulting experience in international business environments, recognized for best-in-class HR practices.
  • Handles complexity well, can handle multiple tasks and initiatives at the same time - can prioritise and organise your own and the P&C team's time and energy into the most important topics in service of our outcomes; able to stay calm in chaos and propose solutions in the best interests of the organisation and outcomes.
  • Systems thinking with proven ability to work effectively across multiple business areas, teams, and key leadership networks in a fast-paced environment.
  • Purpose-driven with genuine interest in people, ability to create real connections, interest in making an impact at affiliate and global level, open to long-term international career development.
  • Bachelor's or University degree in Human Resources (an advanced degree is preferred); strong written and verbal communication skills; fluent English is a must; knowledge of Hindi is a plus.
  • Experience in the healthcare or pharmaceutical industry is highly preferred.
  • Travel 25-30% of time
Responsibilities
  • Influence & Trust: You must have the ability to influence with courageous authenticity, build trust with individuals at all levels, and challenge the status quo when appropriate without relying on formal reporting lines.
  • Coaching: You will act as a trusted strategic partner, a credible activist, and a coach to creative leadership and the country leadership team. You will engage in honest, authentic, and open dialogue at all levels to unlock the greatness in our people and organization.
  • Strategic Alignment: You will translate business strategy into P&C strategies for the leadership areas and drive fit-for-purpose implementation and pull-through.
  • Organizational Transformation: You will be a key enabler of organizational transformation, advancing organizational design and effectiveness, including driving shifts in mindset, behaviors, and ways of working.
  • Data-Driven Culture: You will focus on data-driven insights to inform your actions and the overall P&C strategy, aiming to create a high-performance, integrity-driven culture where employees can thrive.
Desired Qualifications
  • Experience in the healthcare or pharmaceutical industry is highly preferred.
  • Bachelor's degree in Human Resources (an advanced degree is preferred)
  • Knowledge of Hindi is a plus.

Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.

Company Size

1-10

Company Stage

IPO

Headquarters

Basel, Switzerland

Founded

1896

Your Connections

People at Roche who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • VENTANA PTEN RxDx creates a new prostate cancer companion-diagnostic revenue stream.
  • PathAI acquisition expands AI-driven diagnostics and global digital pathology workflow integration.
  • Nurix collaboration extends Roche into BTK degraders across hematology and immunology.

What critics are saying

  • Swiss franc strength continues depressing reported earnings from Roche’s Swiss cost base.
  • Upcoming patent expirations threaten legacy pharmaceutical revenue before new launches mature.
  • Obesity competition from Novo Nordisk and Eli Lilly leaves CT-388 behind.

What makes Roche unique

  • Roche unites pharmaceuticals, diagnostics, and digital pathology across healthcare workflows.
  • Founded in Basel in 1896, Roche built scale through branded medicines.
  • Genentech acquisition made Roche the world’s largest biotechnology company.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Company News

Dealroom.co
Apr 16th, 2026
SAGA company information, funding & investors

SAGA, providing cancer companion diagnostic testing of tissue and non-invasive monitoring of circulating tumor dna (ctdna). Here you'll find information about their funding, investors and team.

Yahoo Finance
Apr 13th, 2026
Roche receives CE mark for Elecsys NfL blood test to detect neuroinflammation in multiple sclerosis

Roche has received CE mark approval for its Elecsys Neurofilament Light Chain blood test to detect neuroinflammation in adults with relapsing remitting multiple sclerosis. The test measures NfL, a protein released during nerve cell injury, providing insight into neuroaxonal damage associated with the disease. Multiple sclerosis affects over 2.9 million people worldwide. Whilst early and regular monitoring is critical, patients often struggle to access routine MRI scans. The minimally invasive blood test offers a more accessible alternative, complementing clinical assessments and potentially enabling earlier intervention. The test runs on Roche's widely available cobas instruments, delivering standardised results and requiring only a simple blood sample. This reduces the need for patients to travel to specialist centres, making frequent monitoring more practical where traditional testing faces geographic, financial or logistical barriers.

Bizwatch
Apr 12th, 2026
Roche invests $20M in degrader-antibody conjugate platform via C4 Therapeutics deal worth up to $1B

Roche has partnered with C4 Therapeutics to develop degrader-antibody conjugates (DACs), marking a $20 million upfront payment with potential milestone payments exceeding $1 billion. The collaboration targets cancer therapeutics using C4's Torpedo platform. DACs represent a next-generation approach to antibody-drug conjugates (ADCs). Whilst ADCs attach cytotoxic drugs to antibodies, DACs use targeted protein degradation payloads to selectively eliminate specific proteins within cancer cells, potentially reducing toxicity and drug resistance whilst accessing previously difficult targets. Amongst Korean listed companies, Orum Therapeutics leads DAC development, having licensed ORM-6151 to Bristol Myers Squibb in 2023. Y-Biologics partnered with Ubix Therapeutics, whilst Oscotec is developing three DAC pipelines through subsidiary Genosco, targeting technology transfers after 2028.

Yahoo Finance
Mar 30th, 2026
Roche gets FDA clearance for cobas c703 and ISE neo lab testing units with 2,000 tests per hour

Roche has received FDA 510(k) clearance for its cobas c703 and cobas ISE neo analytical units, designed to enhance laboratory efficiency through increased automation and testing capacity. The units are part of Roche's cobas pro integrated solutions platform. The cobas c703 delivers up to 2,000 tests per hour with 70 reagent positions, doubling clinical chemistry throughput whilst reducing reagent reloads. The cobas ISE neo provides up to 1,800 tests per hour with automated maintenance, reducing hands-on time and plastic waste compared to previous systems. Both units feature monthly operator maintenance to improve uptime and help laboratories address staffing shortages and growing test volumes. Roche has over 4,000 cobas analysers installed across the United States.

Yahoo Finance
Mar 30th, 2026
Roche launches cobas MPX-E assay, 4-in-1 donor screening test for HIV, HCV, HBV and HEV

Roche has launched the cobas MPX-E assay, a four-in-one donor screening test that simultaneously detects HIV, Hepatitis C, B and E viruses. The test is now available in countries accepting the CE mark. The assay consolidates detection of four major viral targets into a single workflow, improving laboratory efficiency and reducing costs. It features dual-target detection for HIV-1 and enhanced sensitivity for Hepatitis E, which causes an estimated 20 million infections and 70,000 deaths annually worldwide. The test runs on Roche's fully automated cobas x800 systems, which process over 10 million tests monthly across laboratories globally. The ready-to-load reagents enable up to eight hours of walk-away time. The nucleic acid testing blood screening market is valued at approximately 800 million Swiss francs globally, with an expected annual growth rate of 2% through 2029.

INACTIVE